đ†đ„đšđ›đšđ„ Ultomiris đŒđšđ«đ€đžđ­ Competitive Intelligence & Emerging Opportunities
The Ultomiris Drug Market is experiencing significant growth due to the increasing prevalence of rare autoimmune and hematologic disorders, rising awareness about complement-mediated diseases, and advancements in biologic therapies. Ultomiris (ravulizumab), a long-acting complement C5 inhibitor, has emerged as a breakthrough treatment for several life-threatening conditions, driving...
0 Commentaires 0 Parts 51 Vue 0 Aperçu